文献速递艾滋病与性传播感染医院感染防控

美国HIV阳性逝者器官捐献者全国特征分析

National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该前瞻性研究纳入2016年3月至2020年3月美国HOPE法案下92例HIV阳性或假阳性捐献者(58例阳性、34例假阳性),共捐献177个器官。HIV阳性捐献者中42%检出主要耐药突变,但整合酶链转移抑制剂相关耐药罕见,对安全性构成令人安心的信号。

要点

  • HIV阳性捐献者中主要耐药突变常见(42%),但整合酶抑制剂耐药仅4%。
  • 多数HIV阳性捐献者已获诊断(71%),其中90%接受ART、68%病毒载量<400 copies/mL。
  • HIV阳性捐献者HBV、梅毒、CMV血清阳性率高于假阳性捐献者。

核心结论

  • HIV阳性捐献者器官使用逐年增加,主要HIV耐药突变常见但整合酶链转移抑制剂相关耐药罕见,安全性令人安心。

研究设计与样本

  • 前瞻性研究,纳入HOPE法案下HIV D+/R+移植研究中92例捐献者(58例HIV阳性、34例假阳性),共捐献177个器官(131肾、46肝)。

主要发现

  • HIV阳性较假阳性捐献者HBV流行率更高(16% vs 0%)、梅毒更高(16% vs 0%)、CMV更高(91% vs 58%),HCV病毒血症相似(2% vs 6%)。
  • 71%的HIV阳性捐献者有已知HIV诊断,其中90%处方ART、68%病毒载量<400 copies/mL。
  • CD4 T细胞计数中位数194/µL(IQR 77-331/µL),CD4百分比中位数27.0%(IQR 16.8%-36.1%)。
  • 主要HIV耐药突变检出率42%,包括非核苷类逆转录酶抑制剂33%、整合酶链转移抑制剂4%、多类耐药13%。
  • 血清ART检出率46%,与病史匹配。

临床怎么用

  • 评估HIV阳性捐献者时应关注耐药突变谱,尤其是整合酶抑制剂相关耐药,以指导受者ART方案选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Organ transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV (HIV D+/R+) presents risks of donor-derived infections. Understanding clinical, immunologic, and virologic characteristics of HIV-positive donors is critical for safety. METHODS: We performed a prospective study of donors with HIV-positive and HIV false-positive (FP) test results within the HIV Organ Policy Equity (HOPE) Act in Action studies of HIV D+/R+ transplantation (ClinicalTrials.gov NCT02602262, NCT03500315, and NCT03734393). We compared clinical characteristics in HIV-positive versus FP donors. We measured CD4 T cells, HIV viral load (VL), drug resistance mutations (DRMs), coreceptor tropism, and serum antiretroviral therapy (ART) detection, using mass spectrometry in HIV-positive donors. RESULTS: Between March 2016 and March 2020, 92 donors (58 HIV positive, 34 FP), representing 98.9% of all US HOPE donors during this period, donated 177 organs (131 kidneys and 46 livers). Each year the number of donors increased. The prevalence of hepatitis B (16% vs 0%), syphilis (16% vs 0%), and cytomegalovirus (CMV; 91% vs 58%) was higher in HIV-positive versus FP donors; the prevalences of hepatitis C viremia were similar (2% vs 6%). Most HIV-positive donors (71%) had a known HIV diagnosis, of whom 90% were prescribed ART and 68% had a VL <400 copies/mL. The median CD4 T-cell count (interquartile range) was 194/µL (77-331/µL), and the median CD4 T-cell percentage was 27.0% (16.8%-36.1%). Major HIV DRMs were detected in 42%, including nonnucleoside reverse-transcriptase inhibitors (33%), integrase strand transfer inhibitors (4%), and multiclass (13%). Serum ART was detected in 46% and matched ART by history. CONCLUSION: The use of HIV-positive donor organs is increasing. HIV DRMs are common, yet resistance that would compromise integrase strand transfer inhibitor-based regimens is rare, which is reassuring regarding safety.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Werbel WA, Brown DM, Kusemiju OT, et al. National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States. Clin Infect Dis. 2022. PMID: 34453519. doi:10.1093/cid/ciab743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。